Krystal Biotech, Inc. — Form 8-K
Filed November 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
Krystal Biotech reported Q3 2026 VYJUVEK net product revenue of $127.3 million (30% YoY growth); cumulative revenue since launch reached $1.1 billion. The company completed pricing negotiations in Germany and Italy, with Italy launch expected early 2027. The Board authorized a $400 million share repurchase program to be deployed opportunistically over the next two years. Cash and investments totaled $1.2 billion as of September 30, 2026.
Why this rating
Strong VYJUVEK revenue growth and margin expansion (94%) with profitability achieved; $400M buyback (11% of market cap) signals confidence but is modest capital deployment. Pipeline progress is meaningful but early-stage. Moderate development for $3.5B company.
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.